Chromone-based monoamine oxidase B inhibitor with potential iron-chelating activity for the treatment of Alzheimer’s disease

References

• Alzheimer's Association. Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2021;17:327–406.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Ahmad R, Khare SK. Alzheimer’s disease and its treatment by different approaches: a review. Eur J Med Chem. 2021;216:113320.
   PubMed Web of Science ®Google Scholar
• Abeysinghe A, Deshapriya R, Udawatte C. Alzheimer’s disease; a review of the pathophysiological basis and therapeutic interventions. Life Sci. 2020;256:117996.
   PubMed Web of Science ®Google Scholar
• Kepp KP. Bioinorganic chemistry of Alzheimer’s disease. Chem Rev. 2012;112(10):5193–5239.
   PubMed Web of Science ®Google Scholar
• Telling ND, Everett J, Collingwood JF, Dobson J, van der Laan G, Gallagher JJ, Wang J, Hitchcock AP. Iron biochemistry is correlated with amyloid plaque morphology in an established mouse model of Alzheimer’s disease. Cell Chem Biol. 2017;24(10):1205–1215 e3.
   PubMed Web of Science ®Google Scholar
• Savelieff MG, Nam G, Kang J, Lee HJ, Lee M, Lim MH. Development of multifunctional molecules as potential therapeutic candidates for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis in the last decade. Chem Rev. 2019;119(2):1221–1322.
   PubMed Web of Science ®Google Scholar
• Bai R, Guo J, Ye XY, Xie Y, Xie T. Oxidative stress: the core pathogenesis and mechanism of Alzheimer’s disease. Ageing Res Rev. 2022;77:101619.
   PubMed Web of Science ®Google Scholar
• Lane DJR, Ayton S, Bush AI. Iron and Alzheimer’s disease: an update on emerging mechanisms. J Alzheimers Dis. 2018;64(s1):S379–S395.
   PubMedGoogle Scholar
• Mesiti F, Chavarria D, Gaspar A, Alcaro S, Borges F. The chemistry toolbox of multitarget-directed ligands for Alzheimer’s disease. Eur J Med Chem. 2019;181:111572.
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhou T, Bai R, Xie Y. Hydroxypyridinone-based iron chelators with broad-ranging biological activities. J Med Chem. 2020;63(23):14470–14501.
   PubMed Web of Science ®Google Scholar
• Cong L, Dong X, Wang Y, Deng Y, Li B, Dai R. On the role of synthesized hydroxylated chalcones as dual functional amyloid-beta aggregation and ferroptosis inhibitors for potential treatment of Alzheimer’s disease. Eur J Med Chem. 2019;166:11–21.
   PubMed Web of Science ®Google Scholar
• Tripathi AC, Upadhyay S, Paliwal S, Saraf SK. Privileged scaffolds as MAO inhibitors: retrospect and prospects. Eur J Med Chem. 2018;145:445–497.
   PubMed Web of Science ®Google Scholar
• Manzoor S, Hoda N. A comprehensive review of monoamine oxidase inhibitors as anti-Alzheimer’s disease agents: a review. Eur J Med Chem. 2020;206:112787.
   PubMed Web of Science ®Google Scholar
• Zhou J, Jiang X, He S, Jiang H, Feng F, Liu W, Qu W, Sun H. Rational design of multitarget-directed ligands: strategies and emerging paradigms. J Med Chem. 2019;62(20):8881–8914.
   PubMed Web of Science ®Google Scholar
• Wang T, Liu XH, Guan J, Ge S, Wu MB, Lin JP, Yang LR. Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer’s disease. Eur J Med Chem. 2019;169:200–223.
   PubMed Web of Science ®Google Scholar
• Carradori S, Silvestri R. New frontiers in selective human MAO-B inhibitors. J Med Chem. 2015;58(17):6717–6732.
   PubMed Web of Science ®Google Scholar
• Liu W, Lang M, Youdim MBH, Amit T, Sun Y, Zhang Z, Wang Y, Weinreb O. Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer’s disease. Neuropharmacology. 2016;109:376–385.
   PubMed Web of Science ®Google Scholar
• Mechlovich D, Amit T, Mandel SA, Bar-Am O, Bloch K, Vardi P, Youdim MBH. The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage. J Pharmacol Exp Ther. 2010;333(3):874–882.
   PubMed Web of Science ®Google Scholar
• Esteban G, Allan J, Samadi A, Mattevi A, Unzeta M, Marco-Contelles J, Binda C, Ramsay RR. Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer’s disease. Biochim Biophys Acta. 2014;1844(6):1104–1110.
   PubMed Web of Science ®Google Scholar
• Zhang C, Yang K, Yu S, Su J, Yuan S, Han J, Chen Y, Gu J, Zhou T, Bai R, et al. Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer’s disease. Eur J Med Chem. 2019; 180:367–382.
   PubMed Web of Science ®Google Scholar
• Pachón-Angona I, Refouvelet B, Andrýs R, Martin H, Luzet V, Iriepa I, Moraleda I, Diez-Iriepa D, Oset-Gasque M-J, Marco-Contelles J, et al. Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy. J Enzyme Inhib Med Chem. 2019;34(1):479–489.
   PubMed Web of Science ®Google Scholar
• Jiang X, Guo J, Zhang C, Gu J, Zhou T, Bai R, Xie Y. Discovery of benzamide-hydroxypyridinone hybrids as potent multi-targeting agents for the treatment of Alzheimer’s disease. J Enzyme Inhib Med Chem. 2021;36(1):2045–2054.
   PubMed Web of Science ®Google Scholar
• Reis J, Cagide F, Chavarria D, Silva T, Fernandes C, Gaspar A, Uriarte E, Remião F, Alcaro S, Ortuso F, et al. Discovery of new chemical entities for old targets: insights on the lead optimization of chromone-based monoamine oxidase B (MAO-B) inhibitors. J Med Chem. 2016;59(12):5879–5893.
   PubMed Web of Science ®Google Scholar
• Fonseca A, Reis J, Silva T, Matos MJ, Bagetta D, Ortuso F, Alcaro S, Uriarte E, Borges F. Coumarin versus chromone monoamine oxidase B inhibitors: quo vadis? J Med Chem. 2017;60(16):7206–7212.
   PubMed Web of Science ®Google Scholar
• Reis J, Gaspar A, Milhazes N, Borges F. Chromone as a privileged scaffold in drug discovery: recent advances. J Med Chem. 2017;60(19):7941–7957.
   PubMed Web of Science ®Google Scholar
• Mi Z, Gan B, Yu S, Guo J, Zhang C, Jiang X, Zhou T, Su J, Bai R, Xie Y. Dual-target anti-Alzheimer’s disease agents with both iron ion chelating and monoamine oxidase-B inhibitory activity. J Enzyme Inhib Med Chem. 2019;34(1):1489–1497.
   PubMed Web of Science ®Google Scholar
• Rullo M, Catto M, Carrieri A, de Candia M, Altomare CD, Pisani L. Chasing ChEs-MAO B multi-targeting 4-aminomethyl-7-benzyloxy-2-chromen-2-ones. Molecules. 2019;24(24):4507.
   PubMed Web of Science ®Google Scholar
• Zeng H, Wu X. Alzheimer’s disease drug development based on computer-aided drug design. Eur J Med Chem. 2016; 121:851–863.
   PubMed Web of Science ®Google Scholar
• Gaspar A, Silva T, Yanez M, Vina D, Orallo F, Ortuso F, Uriarte E, Alcaro S, Borges F. Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors. J Med Chem. 2011;54(14):5165–5173.]
   PubMed Web of Science ®Google Scholar
• Masaldan S, Bush AI, Devos D, Rolland AS, Moreau C. Striking while the iron is hot: iron metabolism and ferroptosis in neurodegeneration. Free Radic Biol Med. 2019;133:221–233.
   PubMed Web of Science ®Google Scholar
• Xie Y-Y, Lu Z, Kong X-L, Zhou T, Bansal S, Hider R. Systematic comparison of the mono-, dimethyl- and trimethyl 3-hydroxy-4(1H)-pyridones – attempted optimization of the orally active iron chelator, deferiprone. Eur J Med Chem. 2016;115:132–140.
   PubMed Web of Science ®Google Scholar
• Guo J, Zhang Y, Zhang C, Yao C, Zhang J, Jiang X, Zhong Z, Ge J, Zhou T, Bai R, et al. N-propargylamine-hydroxypyridinone hybrids as multitarget agents for the treatment of Alzheimer’s disease. Bioorg Chem. 2021;113:105013.
   PubMed Web of Science ®Google Scholar
• Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. High throughput artificial membrane permeability assay for blood–brain barrier. Eur J Med Chem. 2003;38(3):223–232.
   PubMed Web of Science ®Google Scholar
• Guo J, Mi Z, Jiang X, Zhang C, Guo Z, Li L, Gu J, Zhou T, Bai R, Xie Y. Design, synthesis and biological evaluation of potential anti-AD hybrids with monoamine oxidase B inhibitory and iron-chelating effects. Bioorg Chem. 2021;108:104564.
   PubMed Web of Science ®Google Scholar
• Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, Edmondson DE, Mattevi A. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem. 2007;50(23):5848–5852.
   PubMed Web of Science ®Google Scholar